

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10576047	
	Filing Date		2006-04-14	
	First Named Inventor	Katsuyuki HAMADA		
	Art Unit	1632		
	Examiner Name			
	Attorney Docket Number	TSU-006		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10576047
	Filing Date		2006-04-14
	First Named Inventor	Katsuyuki HAMADA	
	Art Unit	1632	
	Examiner Name		
	Attorney Docket Number	TSU-006	

1	Hamada Katsuyuki et al., Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy, Cancer Research, vol. 63, No. 10, 15 May 2003, 2506-2512	<input type="checkbox"/>
2	Campbell I G et al., A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1, Human Molecular Genetics, vol. 3, No. 4, April 1994, 589-59	<input type="checkbox"/>
3	Casado E et al., Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications, Clinical Cancer Research, vol. 7, No. 8, August 2001, 2496-2504	<input type="checkbox"/>
4	Brown M A et al., The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21, Oncogene, vol. 12, no. 12, 2507-2513	<input type="checkbox"/>
5	Tsukuda Kazunori et al., An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficiency but no toxicity to normal cell, Cancer Research, vol. 62, no. 12, 3438-3447.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.